<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164940">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02079597</url>
  </required_header>
  <id_info>
    <org_study_id>NINJ1-001</org_study_id>
    <nct_id>NCT02079597</nct_id>
  </id_info>
  <brief_title>The Role of Ninjurin-1 During Systemic Inflammation</brief_title>
  <acronym>Ninj1</acronym>
  <official_title>Prospective Study to Analyze Ninjurin-1 and Its Soluble Part During Systemic Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Patrick Meybohm, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospitals</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  With the underlying study the investigators address the question if Ninjurin-1 (Ninj1)
           expression is altered in patients with systemic inflammatory response syndrome (SIRS)
           in comparison to healthy volunteers.

        -  The adhesion molecule Ninj1 is induced following nerve injury where it contributes to
           nerve generation. Besides it is described to facilitate leukocyte migration especially
           in the nervous system.

        -  The investigators hypothesize that Ninj1 expression is increased in SIRS patients,
           which will fortify its impact during inflammation and the transferability from bench to
           bedside.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Ninj1 expression on blood leukocytes</measure>
    <time_frame>one day post surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>grade of systemic inflammation</measure>
    <time_frame>one day post surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>routine inflammatory markers will be used to evaluate the grade of inflammation e.g. procalcitonin (PCT) Interleukin 6, lipopolysaccharide (LPS) binding protein (LBP). Retrospective evaluation for sepsis (bacterial infection)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Soluble Ninj1 concentration/expression rates</measure>
    <time_frame>one day post surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentration will be measured in plasma samples as well as from whole blood culture incubated with 100 ng/ml lipopolysaccharide for 6, 16 and 24 h.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Ninj1 Expression</condition>
  <condition>SIRS</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>Healthy individuals no infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SIRS</arm_group_label>
    <description>SIRS patients no included in an interventional study no peroperative infection</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, plasma, RNA and cDNA extracted from whole blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        SIRS patients: Intensive care unit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  cardiac surgery patients

        Exclusion Criteria:

          -  included in an interventional study

          -  Preoperative Infection (e.g. Endocarditis)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Meybohm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, University Hospital Frankfurt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology, University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Meybohm, MD</last_name>
      <phone>+49 696301</phone>
      <phone_ext>5998</phone_ext>
      <email>patrick.meybohm@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Carla Jennewein, MD</last_name>
      <phone>+49 6906301</phone>
      <phone_ext>87824</phone_ext>
      <email>carla.jennewein@kgu.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospitals</investigator_affiliation>
    <investigator_full_name>Dr. Patrick Meybohm, M.D.</investigator_full_name>
    <investigator_title>PD Dr. Patrick Meybohm, M.D.</investigator_title>
  </responsible_party>
  <keyword>SIRS</keyword>
  <keyword>Ninj1</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Healthy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
